Neuroimmunology Drug Development on March 25-27, 2024 in Boston, United States

Neuroimmunology discovery has continued to expand over the past year, with emerging and continued biology and target investigation against TREM2, RIPK1, ferroptosis, NLRP3, LRRK2, and beyond. However, there are still significant translational barriers to overcome to see clinical success of neuroinflammatory modulators and tackle the huge unmet patient need in neurology.

Characterizing and harnessing functions and interactions of microglia, astrocytes, oligodendrocytes, and infiltrating adaptive immune cells are key to discovering and developing therapies to treat underlying neuroinflammation in Alzheimer's, Parkinson's, multiple sclerosis, and beyond.

Join 100+ biopharma experts from Alector, Lundbeck, Vigil Neuroscience, Biogen, BMS, Muna Therapeutics, Pipeline Therapeutics, PTC Therapeutics, and more, breaking down novel glial biology and neuroinflammatory target investigation, adaptive immunity contributions, state of the art microglial iPSCs, humanized rodent models, neuroinflammatory biomarkers, and early clinical learnings to optimize neuroimmunology translation and develop transformative therapeutics for neurological disorders.

URLs:

Tickets: https://go.evvnt.com/2031693-2?pid=10008

Brochure: https://go.evvnt.com/2031693-4?pid=10008

Prices:
Industry Pricing - Conference Only: USD 2999.00,
Industry Pricing - Conference + Workshop Day: USD 4297.00,
Vendor Pricing - Conference + Workshop Day: USD 5197.00,
Vendor Pricing - Conference Only: USD 3699.00

Speakers: Akshata Almad - Senior Scientist, Neuroscience Merck and Co, Andrew Kaplan - Senior Scientist, Neuroscience TRC Bristol Myers Squibb, Angela Minnella - Director, Neuroscience PTC Therapeutics, Borislav Dejanovic - Director, Translational Sciences and External Innovation Vigil Neuroscience, Choya Yoon - Associate Principal Scientist, Neuroimmunology Merck and Co, Christian Mirescu - Vice President and Head of Neuroimmunology Vigil Neuroscience, Courtney Easley-Neal - Director, Head of Translational Models Department Eisai, Dimitry Ofengeim - Head of Precision Neurology and Neuroinflammation Cluster Sanofi, Dong-Seok Kim - Founder and Chief Executive Officer AevisBio Inc., Enchi Liu - Vice President, Translational Sciences Tranquis Therapeutics Inc., Fabrizio Gasparini - Executive Director, Head of Neuroinflammation Novartis AG, Francesca Rapino - Senior Scientist Sanofi, Gaia Skibinski - Senior Vice President, Biology Herophilus, Gary Romano - Chief Medical Officer Alector Pharmaceuticals LLC, Han-Joo Kim - Chief Executive Officer Imnewrun Biosciences Inc., James Fink - Director, Epilepsy Lead Quiver Bioscience, Jean-Philippe Courade - Chief Scientific Officer Discoveric Bio, Jim Ray - Director, Neurodegeneration Consortium MD Anderson Cancer Center, Katia Karalis - Executive Director, Research and Development, Head of Human Systems for Disease Modeling Regeneron Pharmaceuticals Inc, Kelly Pike - Senior Director, Head of Translational Sciences and Disease Strategy Ventus Therapeutics, Laurence Goffin - Director and Cluster Head for Neuroinflammation and Neuroimmunology H. Lundbeck A/S, Manuela Polydoro - Vice President, Head of Translational Medicine Muna Therapeutics, Martin Jacko - Chief Executive Officer Aperture Therapeutics, Michelle Sidor - Director, Neuroscience Alchemab Therapeutics Ltd, Nicole Coufal - Associate Professor University of California San Diego, Olga Liaudanskaya - Assistant Professor University of Cincinnati, Paul Ashton - Chief Executive Officer Inflammasome Therapeutics, Peng Jiang - Associate Professor Rutgers University, Richard Ransohoff - Co-Founder and Chief Medical Officer Third Rock Ventures LLC, Sarah Jolly - Senior Research Associate – Operational leadership team University College London, Simona Lange - Senior Scientist Roche, Stephen Huhn - Chief Medical Officer and Senior Vice President, Clinical Development Pipeline Therapeutics, Tarek Samad - Senior Vice President and Global Head, Research Lundbeck, Thomas Tamsett - Director of Neuroscience, RU Neuroscience and Immunology EDM Serono, Xiaoyu Liu - Scientist Biogen, Yongjie Yang - Professor, Neurology Tufts University School of Medicine and Tufts Medical Center, Zhiqiang An Professor and Robert A. Welch - Distinguished University Chair in Chemistry and Vice President, Drug Discovery The University of Texas Health Science Center at Tyler

Time: 07:30 to 17:30